SciELO - Scientific Electronic Library Online

 
vol.37 número3Lei de diretivas antecipadas de vontade no Uruguai: uma intenção louvável com algumas inconsistênciasEsplenectomia laparoscópica em esplenomegalia maciça devido a linfoma não-Hodgkin de zona marginal índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Links relacionados

Compartilhar


Revista Médica del Uruguay

versão impressa ISSN 0303-3295versão On-line ISSN 1688-0390

Resumo

ROCA, Federico; DANZA, Álvaro; PIPPO, Antonella  e  BORGIA, Ignacio. Vaccine-associated immune thrombosis and thrombocytopenia. First national report. Rev. Méd. Urug. [online]. 2021, vol.37, n.3, e701.  Epub 01-Set-2021. ISSN 0303-3295.  https://doi.org/10.29193/rmu.37.3.11.

Introduction:

vaccines against SARS-CoV-2 are an essential tool against the COVID-19 pandemic. The vaccine developed in collaboration with the University of Oxford and the AstraZeneca (AZN) laboratory has proved to be effective, although venous thrombosis have been reported.

Clinical case:

the study presents the case of a 70 year old male patient who, 7 days after receiving the first dose of the AZN vaccination develops deep vein thrombosis (DVT) in the lower extremities and pulmonary embolism.

Simultaneously, thrombocytopenia is 15.000/mm3, fibrinogen levels drop D-dimer levels are elevated. The clinical situation leads to the suspicion of vaccine-associated immune thrombosis and thrombocytopenia (VITT). The patient was treated with intravenous immune globulin, methylprednisolone and cryoprecipitates, requiring a filter to be placed in the inferior vena cava. Once platelets count improved, anti-coagulation therapy including apixaban was commenced, evolution being good.

Discussion:

this is the first national report on VITT. Thrombosis after the AZN vaccination may be seen in other vaccines that use the same vaccine platform (inactive adenovirus). Cases have been reported mainly in patients younger than 60 years old and in unusual topographies. In particular, this case presents a male patient that is older than 60 years old, who had already been infected with COVID-19 five months before and who currently consults with thrombosis in regular sites. Therapeutic handling observed international guidelines. The case contributes relevant data both in terms of early diagnosis and therapeutic handling.

Palavras-chave : Thrombocytopenia; Thrombosis; COVID-19 Vaccine AstraZeneca.

        · resumo em Português | Espanhol     · texto em Espanhol     · Espanhol ( pdf )